Pacylex

Grand Opening of Merck Accelerator in Edmonton; Pacylex one of first 4 companies accepted

In partnership with the University of Alberta, Merck launched the Merck Invention Accelerator in a grand opening in Edmonton, Alberta, October 26, 2018. Pacylex was selected as one of the first 4 companies to participate in the accelerator program. This program consists of mentorship, space and funding https://www.tecedmonton.com/what-we-offer/programs-and-accelerators/merck-invention-accelerator/. Mentorship includes scientific and business input from Merck experts and mentorship from the TEC Health Accelerator program to help build, grow and scale PCLX-001. Common office and research space at TEC Edmonton is also provided along with direct access to all University of Alberta facilities. In addition, the company receives a small amount of non-dilutive funding to support the advancement of PCLX-001. This relationship does not require any equity or commercial rights from Pacylex.


https://twitter.com/TECEdmonton/status/1055875219686977536/photo/1?ref_src=twsrc%5Etfw%7Ctwcamp%5Eembeddedtimeline%7Ctwterm%5Eprofile%3ATECEdmonton&ref_url=https%3A%2F%2Fwww.tecedmonton.com%2F


One day prior to the Grand Opening (October 25), Pacylex CEO Michael Weickert, PhD, presented Pacylex at the LifeSciences BC’s Investor Summit in Vancouver (https://lifesciencesbc.ca/event/lifesciences-bc-investor-summit-2018-presented-by-lumira-ventures/). Pacylex was one of only 18 companies chosen to present. Co-sponsored by Lumira Ventures, the Investor Summit brought together stakeholders in the healthcare innovation ecosystem for a day of company pitches, panel discussions and entrepreneurs getting feedback and engagement from a wide range of investor stakeholders including; angel investors, venture capital, corporate ventures and funding foundations.



March 12, 2019